Beta-Seron: Friend or Foe

Did Beta-Seron help your MS or cause you to progress?

&
 

Sep 15 2008

Multiple Sclerosis Drug Therapies

Published by manwithms at 7:22 pm under multiple sclerosis Edit This

I’ve been on all of the FDA approved drug therapies for multiple sclerosis and I would choose not to ever try one if I had the chance to do it over again.

Using beta-seron was the worst of all the therapies for me. Shortly after starting the drug I became obsessed with thoughts of suicide and could no longer walk on my own. I could not even take over half of the typical dosage because of the horrible flu-like symptoms.

I was able to tolerate the flu-like symptoms from avonex after a couple of months. My short-term memory was totally incapacitated and returned back to normal after I quit taking the weekly injections.

Copaxone was very tolerable, but my neurologist felt it was too weak and recommended that I change drugs.

My body couldn’t tolerate rebiff and left me bruised at the injection sites. My mother felt it was the best therapy she had, but her cardiologist made her stop taking it.

Novantrone was tolerable but I got more lesions on my brain so I switched drugs again.

I used tysabri once. I noticed that I could no longer sit without my quardiceps totally losing strength before I lowered myself to the couch. I would also lose control of my bladder. I was weak, depressed and un-motivated for about a month. I never had another embarassing bladder incident since I quit taking tysabri and I returned back to how I was before my tysabri infusion exceot for my weakened quads. I’ve decided to wait for something different like stem cell transplants.

Possibly-related Articles:                                        (auto-generated)

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.
Not A Member? Register for Free!

Some Today.com contributors may have received a fee or a promotional product or service from a manufacturer for promotional consideration, while others receive no consideration at all. Each contributor is responsible for disclosing any such promotional consideration.